{"entity":{"id":"nu-q-cancer","kind":"drug","name":"Nu.Q Cancer","aka":[],"tldr":"VolitionRx's blood test that measures DNA packaging released by dying cells; a version is sold for dogs, and the human multi-cancer test is at preprint stage.","summary":"VolitionRx's multi-cancer evidence in people is a preprint (Pamart et al., medRxiv 2025, not peer-reviewed): 112 of 229 patients with one of 21 cancer types were positive (49%), including 11 of 32 stage I solid cancers (34%), with no false positives among 150 asymptomatic controls, but the cut-off was set at the highest control value, so specificity was 100% by construction. The company's commercial multi-cancer product is the veterinary Nu.Q Vet test. No CE marking of a human cancer screening test was found.","status":"emerging","asOf":"2026-10-29","links":[{"label":"Pamart et al., medRxiv 2025 (preprint)","url":"https://doi.org/10.1101/2025.03.14.25323908"},{"label":"VolitionRx","url":"https://volition.com/"}],"tags":["test","mced","evidence:insufficient"],"related":[],"cancers":[],"sections":[],"technologies":["mced","liquid-biopsy"],"targets":[],"drugs":[],"companies":["volitionrx"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Evidence grade insufficient for the claim that taking this test reduces late-stage diagnosis or cancer deaths: no randomised trial of it has reported either outcome, and its published performance comes from case-control or single-arm studies. The only randomised result for any multi-cancer test, NHS-Galleri, did not show fewer stage III or IV cancers.","The human data are an unreviewed preprint with a cut-off fitted to the controls.","What a result means: a positive result is a reason for further tests, not a diagnosis; a negative result does not rule cancer out and does not replace the screening tests that have been shown to work (bowel, breast, cervical and, where eligible, lung screening)."],"brand":"Nu.Q","modality":"Multi-cancer blood test in development (circulating nucleosome immunoassay)","mechanism":"Immunoassays measure nucleosomes, the protein spools DNA is wound around, and their epigenetic marks in plasma; tumours release more of them as cells die.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/nu-q-cancer/","neighbours":{"technology":[{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"},{"id":"mced","kind":"technology","name":"Multi-cancer early detection (MCED)","route":"/technologies/mced/"}],"company":[{"id":"volitionrx","kind":"company","name":"VolitionRx","route":"/companies/volitionrx/"}]}}